论文部分内容阅读
【目的】比较分析齐拉西酮和氨磺必利治疗女性精神分裂症的疗效和安全性。【方法】将116例女性精神分裂症患者随机分为观察组和对照组，每组各58例。观察组给予氨磺必利治疗，对照组给予齐拉西酮治疗。治疗4周、8周后，比较两组阳性和阴性症状评分(PANSS)、疗效和不良反应发生率。【结果】观察组治疗8周后显效率和有效率与对照组比较差异均无统计学意义(P >0.05)。两组治疗后4周和治疗8周的PANSS评分均显著低于治疗前(P 0.05)。观察组治疗后锥体外系反应、体质量增长、月经改变发生率均显著低于对照组(P 0.05).The PANSS scores were significantly lower 4 and 8 weeks after treatment than the PANSS scores before treatment (P0.05).Extrapyramidal reactions observed after treatment,weight gain,menstrual changes rates were 3.45%,1.72%,and 3.45% respectively in the amisul-pride group were significantly lower than in the ziprasidone control group (χ2=22.486,14.210,14.162,P <0.05).[Conclusion]Amisulpride and ziprasidone treatment of female schizophrenia have a similar effects,but amisulpride has higher security,and is more suitable for female patients with schizophrenia.